Aida Piedra, Medical Director of Early Oncology Clinical Development RandD – Baselga Cancer Research Scholar at AstraZeneca, shared on LinkedIn:
“What an incredible journey these past months have been!
Transitioning from my former Phase 1 Clinical Trials Unit to a completely new perspective on drug development, these months have been full of learning, challenges, and inspiring experiences. I feel incredibly fortunate for how smooth and rewarding this transition into the pharmaceutical industry has been. Attending ESMO in Madrid as an AZ member was one of the highlights – also a great opportunity to catch up with former colleagues and friends.
I am incredibly proud to be part of AstraZeneca and deeply grateful for all the people who have made this new chapter so special – a huge thank you to my colleagues, manager and all the Early Oncology Clinical Development team.
Still so much to look forward to!”
You can also read: AstraZeneca Puts $2 Billion Behind Summit’s Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio
